Amphion Innovations plc
Directors Receive Shares in Lieu of Fees
London and New York, 23 July 2012- Amphion Innovations plc (the “Company”) (LSE: AMP), the developer of medical and technology businesses, announces that the Company has today issued 365,129 ordinary shares, representing 0.27% of the enlarged issued share capital, to certain of its Board members as their directors’ fees for the first and second quarters of 2012, priced at 3.924p, being the average of the closing mid-market price for the five days leading up to the market close on 19 July 2012.
Following this issue, the directors’ shareholdings in the Company are as follows:
|R. James Macaleer||265,129||23,802,862||17.58%|
Director, Anthony Henfrey waived his fees for the first and second quarters of 2012. Admission of the 365,129 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 30 July 2012. Following this allotment the total issued share capital of the Company will increase to 135,374,167 ordinary shares with each share holding one voting right.
For further information please contact
+1 212 210 6224
+44 (0)20 7930 0777
Seymour Pierce Limited, Nominated Advisor
Freddy Crossley/Mark Percy
+44 (0)20 7107 8000
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com